APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chagas Disease Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Chagas Disease Drug Market Outlook and Growth Opportunities 2026

22 December 2025198 pages

Choose your research edition.

Industry ResearchChagas Disease Drug Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Chagas Disease Drug Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Chagas Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chagas Disease Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Chagas Disease Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Chagas Disease Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Chagas Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Chagas Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chagas Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Chagas Disease Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Chagas Disease Drug market include Eisai Co Ltd, Sanofi, Novartis AG, GlaxoSmithKline Plc, Bayer AG, AstraZeneca Plc, Oblita Therapeutics BVBA, Merck & Co Inc and Kancera AB, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Chagas Disease Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Chagas Disease Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Chagas Disease Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Chagas Disease Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Chagas Disease Drug Segment by Company

Eisai Co Ltd

Sanofi

Novartis AG

GlaxoSmithKline Plc

Bayer AG

AstraZeneca Plc

Oblita Therapeutics BVBA

Merck & Co Inc

Kancera AB

Humanigen Inc

Grupo Praxis Pharmaceutical SA

Daiichi Sankyo Co Ltd

Chagas Disease Drug Segment by Type

Cz-007

Cz-008

D-121

DNDI-0690

EPLBS-1246

EPLBS-967

Others

Chagas Disease Drug Segment by Application

Hospital

Clinic

Others

Chagas Disease Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Chagas Disease Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Chagas Disease Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Chagas Disease Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Chagas Disease Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chagas Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chagas Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chagas Disease Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Chagas Disease Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Chagas Disease Drug industry.

Chapter 3: Detailed analysis of Chagas Disease Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Chagas Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Chagas Disease Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Chagas Disease Drug Industry Trends Table 2. Chagas Disease Drug Industry Drivers Table 3. Chagas Disease Drug Industry Opportunities and Challenges Table 4. Chagas Disease Drug Industry Restraints Table 5. Global Chagas Disease Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Chagas Disease Drug Revenue Share by Company (2021-2026) Table 7. Global Chagas Disease Drug Sales Volume by Company (k units) & (2021-2026) Table 8. Global Chagas Disease Drug Sales Volume Share by Company (2021-2026) Table 9. Global Chagas Disease Drug Average Price (US$/unit) of Company (2021-2026) Table 10. Global Chagas Disease Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Chagas Disease Drug Key Company Manufacturing Base & Headquarters Table 12. Global Chagas Disease Drug Company, Product Type & Application Table 13. Global Chagas Disease Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Chagas Disease Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Cz-007 Table 18. Significant Companies of Cz-008 Table 19. Significant Companies of D-121 Table 20. Significant Companies of DNDI-0690 Table 21. Significant Companies of EPLBS-1246 Table 22. Significant Companies of EPLBS-967 Table 23. Significant Companies of Others Table 24. Global Chagas Disease Drug Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Chagas Disease Drug Sales Volume by Type (2021-2026) & (k units) Table 26. Global Chagas Disease Drug Sales Volume by Type (2027-2032) & (k units) Table 27. Global Chagas Disease Drug Sales Volume Share by Type (2021-2026) Table 28. Global Chagas Disease Drug Sales Volume Share by Type (2027-2032) Table 29. Global Chagas Disease Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Chagas Disease Drug Sales Value by Type (2021-2026) & (US$ Million) Table 31. Global Chagas Disease Drug Sales Value by Type (2027-2032) & (US$ Million) Table 32. Global Chagas Disease Drug Sales Value Share by Type (2021-2026) Table 33. Global Chagas Disease Drug Sales Value Share by Type (2027-2032) Table 34. Significant Companies of Hospital Table 35. Significant Companies of Clinic Table 36. Significant Companies of Others Table 37. Global Chagas Disease Drug Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Chagas Disease Drug Sales Volume by Application (2021-2026) & (k units) Table 39. Global Chagas Disease Drug Sales Volume by Application (2027-2032) & (k units) Table 40. Global Chagas Disease Drug Sales Volume Share by Application (2021-2026) Table 41. Global Chagas Disease Drug Sales Volume Share by Application (2027-2032) Table 42. Global Chagas Disease Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Chagas Disease Drug Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Chagas Disease Drug Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Chagas Disease Drug Sales Value Share by Application (2021-2026) Table 46. Global Chagas Disease Drug Sales Value Share by Application (2027-2032) Table 47. Global Chagas Disease Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 48. Global Chagas Disease Drug Sales by Region (2021-2026) & (k units) Table 49. Global Chagas Disease Drug Sales Market Share by Region (2021-2026) Table 50. Global Chagas Disease Drug Sales by Region (2027-2032) & (k units) Table 51. Global Chagas Disease Drug Sales Market Share by Region (2027-2032) Table 52. Global Chagas Disease Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Chagas Disease Drug Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Chagas Disease Drug Sales Value Share by Region (2021-2026) Table 55. Global Chagas Disease Drug Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Chagas Disease Drug Sales Value Share by Region (2027-2032) Table 57. Global Chagas Disease Drug Market Average Price (US$/unit) by Region (2021-2026) Table 58. Global Chagas Disease Drug Market Average Price (US$/unit) by Region (2027-2032) Table 59. Global Chagas Disease Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 60. Global Chagas Disease Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Chagas Disease Drug Sales by Country (2021-2026) & (k units) Table 62. Global Chagas Disease Drug Sales Market Share by Country (2021-2026) Table 63. Global Chagas Disease Drug Sales by Country (2027-2032) & (k units) Table 64. Global Chagas Disease Drug Sales Market Share by Country (2027-2032) Table 65. Global Chagas Disease Drug Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Chagas Disease Drug Sales Value Market Share by Country (2021-2026) Table 67. Global Chagas Disease Drug Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Chagas Disease Drug Sales Value Market Share by Country (2027-2032) Table 69. Eisai Co Ltd Company Information Table 70. Eisai Co Ltd Business Overview Table 71. Eisai Co Ltd Chagas Disease Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Eisai Co Ltd Chagas Disease Drug Product Portfolio Table 73. Eisai Co Ltd Recent Development Table 74. Sanofi Company Information Table 75. Sanofi Business Overview Table 76. Sanofi Chagas Disease Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Sanofi Chagas Disease Drug Product Portfolio Table 78. Sanofi Recent Development Table 79. Novartis AG Company Information Table 80. Novartis AG Business Overview Table 81. Novartis AG Chagas Disease Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Novartis AG Chagas Disease Drug Product Portfolio Table 83. Novartis AG Recent Development Table 84. GlaxoSmithKline Plc Company Information Table 85. GlaxoSmithKline Plc Business Overview Table 86. GlaxoSmithKline Plc Chagas Disease Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. GlaxoSmithKline Plc Chagas Disease Drug Product Portfolio Table 88. GlaxoSmithKline Plc Recent Development Table 89. Bayer AG Company Information Table 90. Bayer AG Business Overview Table 91. Bayer AG Chagas Disease Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Bayer AG Chagas Disease Drug Product Portfolio Table 93. Bayer AG Recent Development Table 94. AstraZeneca Plc Company Information Table 95. AstraZeneca Plc Business Overview Table 96. AstraZeneca Plc Chagas Disease Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. AstraZeneca Plc Chagas Disease Drug Product Portfolio Table 98. AstraZeneca Plc Recent Development Table 99. Oblita Therapeutics BVBA Company Information Table 100. Oblita Therapeutics BVBA Business Overview Table 101. Oblita Therapeutics BVBA Chagas Disease Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Oblita Therapeutics BVBA Chagas Disease Drug Product Portfolio Table 103. Oblita Therapeutics BVBA Recent Development Table 104. Merck & Co Inc Company Information Table 105. Merck & Co Inc Business Overview Table 106. Merck & Co Inc Chagas Disease Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Merck & Co Inc Chagas Disease Drug Product Portfolio Table 108. Merck & Co Inc Recent Development Table 109. Kancera AB Company Information Table 110. Kancera AB Business Overview Table 111. Kancera AB Chagas Disease Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Kancera AB Chagas Disease Drug Product Portfolio Table 113. Kancera AB Recent Development Table 114. Humanigen Inc Company Information Table 115. Humanigen Inc Business Overview Table 116. Humanigen Inc Chagas Disease Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Humanigen Inc Chagas Disease Drug Product Portfolio Table 118. Humanigen Inc Recent Development Table 119. Grupo Praxis Pharmaceutical SA Company Information Table 120. Grupo Praxis Pharmaceutical SA Business Overview Table 121. Grupo Praxis Pharmaceutical SA Chagas Disease Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Grupo Praxis Pharmaceutical SA Chagas Disease Drug Product Portfolio Table 123. Grupo Praxis Pharmaceutical SA Recent Development Table 124. Daiichi Sankyo Co Ltd Company Information Table 125. Daiichi Sankyo Co Ltd Business Overview Table 126. Daiichi Sankyo Co Ltd Chagas Disease Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Daiichi Sankyo Co Ltd Chagas Disease Drug Product Portfolio Table 128. Daiichi Sankyo Co Ltd Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Chagas Disease Drug Distributors List Table 132. Chagas Disease Drug Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Chagas Disease Drug Product Image Figure 2. Global Chagas Disease Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chagas Disease Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Chagas Disease Drug Sales (2021-2032) & (k units) Figure 5. Global Chagas Disease Drug Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Chagas Disease Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Cz-007 Image Figure 10. Cz-008 Image Figure 11. D-121 Image Figure 12. DNDI-0690 Image Figure 13. EPLBS-1246 Image Figure 14. EPLBS-967 Image Figure 15. Others Image Figure 16. Global Chagas Disease Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global Chagas Disease Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 18. Global Chagas Disease Drug Sales Volume Share by Type (2021-2032) Figure 19. Global Chagas Disease Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Chagas Disease Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Chagas Disease Drug Sales Value Share by Type (2021-2032) Figure 22. Hospital Image Figure 23. Clinic Image Figure 24. Others Image Figure 25. Global Chagas Disease Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Chagas Disease Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Chagas Disease Drug Sales Volume Share by Application (2021-2032) Figure 28. Global Chagas Disease Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Chagas Disease Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Chagas Disease Drug Sales Value Share by Application (2021-2032) Figure 31. Global Chagas Disease Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 32. Global Chagas Disease Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Chagas Disease Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Chagas Disease Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Chagas Disease Drug Sales Value (2021-2032) & (US$ Million) Figure 36. North America Chagas Disease Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Chagas Disease Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Chagas Disease Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Chagas Disease Drug Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Chagas Disease Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Chagas Disease Drug Sales Value (2021-2032) & (US$ Million) Figure 42. South America Chagas Disease Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Chagas Disease Drug Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Chagas Disease Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Chagas Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Chagas Disease Drug Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Chagas Disease Drug Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • Cz-007
  • Cz-008
  • D-121
  • DNDI-0690
  • EPLBS-1246
  • EPLBS-967
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Eisai Co Ltd
  • Sanofi
  • Novartis AG
  • GlaxoSmithKline Plc
  • Bayer AG
  • AstraZeneca Plc
  • Oblita Therapeutics BVBA
  • Merck & Co Inc
  • Kancera AB
  • Humanigen Inc
  • Grupo Praxis Pharmaceutical SA
  • Daiichi Sankyo Co Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Chagas Disease Drug Sales Value (2021-2032)
  4. 1.2.2 Global Chagas Disease Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Chagas Disease Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Chagas Disease Drug Market Dynamics
  1. 2.1 Chagas Disease Drug Industry Trends
  2. 2.2 Chagas Disease Drug Industry Drivers
  3. 2.3 Chagas Disease Drug Industry Opportunities and Challenges
  4. 2.4 Chagas Disease Drug Industry Restraints
3 Chagas Disease Drug Market by Company
  1. 3.1 Global Chagas Disease Drug Company Revenue Ranking in 2025
  2. 3.2 Global Chagas Disease Drug Revenue by Company (2021-2026)
  3. 3.3 Global Chagas Disease Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Chagas Disease Drug Average Price by Company (2021-2026)
  5. 3.5 Global Chagas Disease Drug Company Ranking (2024-2026)
  6. 3.6 Global Chagas Disease Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Chagas Disease Drug Company Product Type and Application
  8. 3.8 Global Chagas Disease Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Chagas Disease Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Chagas Disease Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Chagas Disease Drug Market by Type
  1. 4.1 Chagas Disease Drug Type Introduction
  2. 4.1.1 Cz-007
  3. 4.1.2 Cz-008
  4. 4.1.3 D-121
  5. 4.1.4 DNDI-0690
  6. 4.1.5 EPLBS-1246
  7. 4.1.6 EPLBS-967
  8. 4.1.7 Others
  9. 4.2 Global Chagas Disease Drug Sales Volume by Type
  10. 4.2.1 Global Chagas Disease Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Chagas Disease Drug Sales Volume by Type (2021-2032)
  12. 4.2.3 Global Chagas Disease Drug Sales Volume Share by Type (2021-2032)
  13. 4.3 Global Chagas Disease Drug Sales Value by Type
  14. 4.3.1 Global Chagas Disease Drug Sales Value by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Chagas Disease Drug Sales Value by Type (2021-2032)
  16. 4.3.3 Global Chagas Disease Drug Sales Value Share by Type (2021-2032)
5 Chagas Disease Drug Market by Application
  1. 5.1 Chagas Disease Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Chagas Disease Drug Sales Volume by Application
  6. 5.2.1 Global Chagas Disease Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Chagas Disease Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Chagas Disease Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Chagas Disease Drug Sales Value by Application
  10. 5.3.1 Global Chagas Disease Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Chagas Disease Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Chagas Disease Drug Sales Value Share by Application (2021-2032)
6 Chagas Disease Drug Regional Sales and Value Analysis
  1. 6.1 Global Chagas Disease Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Chagas Disease Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Chagas Disease Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Chagas Disease Drug Sales by Region (2027-2032)
  5. 6.3 Global Chagas Disease Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Chagas Disease Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Chagas Disease Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Chagas Disease Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Chagas Disease Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Chagas Disease Drug Sales Value (2021-2032)
  12. 6.6.2 North America Chagas Disease Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Chagas Disease Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Chagas Disease Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Chagas Disease Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Chagas Disease Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Chagas Disease Drug Sales Value (2021-2032)
  21. 6.9.2 South America Chagas Disease Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Chagas Disease Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Chagas Disease Drug Sales Value Share by Country, 2025 VS 2032
7 Chagas Disease Drug Country-level Sales and Value Analysis
  1. 7.1 Global Chagas Disease Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Chagas Disease Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Chagas Disease Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Chagas Disease Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Chagas Disease Drug Sales by Country (2027-2032)
  6. 7.4 Global Chagas Disease Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Chagas Disease Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Chagas Disease Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Chagas Disease Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Chagas Disease Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Chagas Disease Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eisai Co Ltd
  2. 8.1.1 Eisai Co Ltd Company Information
  3. 8.1.2 Eisai Co Ltd Business Overview
  4. 8.1.3 Eisai Co Ltd Chagas Disease Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Eisai Co Ltd Chagas Disease Drug Product Portfolio
  6. 8.1.5 Eisai Co Ltd Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Chagas Disease Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Chagas Disease Drug Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Novartis AG
  14. 8.3.1 Novartis AG Company Information
  15. 8.3.2 Novartis AG Business Overview
  16. 8.3.3 Novartis AG Chagas Disease Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis AG Chagas Disease Drug Product Portfolio
  18. 8.3.5 Novartis AG Recent Developments
  19. 8.4 GlaxoSmithKline Plc
  20. 8.4.1 GlaxoSmithKline Plc Company Information
  21. 8.4.2 GlaxoSmithKline Plc Business Overview
  22. 8.4.3 GlaxoSmithKline Plc Chagas Disease Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Plc Chagas Disease Drug Product Portfolio
  24. 8.4.5 GlaxoSmithKline Plc Recent Developments
  25. 8.5 Bayer AG
  26. 8.5.1 Bayer AG Company Information
  27. 8.5.2 Bayer AG Business Overview
  28. 8.5.3 Bayer AG Chagas Disease Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Bayer AG Chagas Disease Drug Product Portfolio
  30. 8.5.5 Bayer AG Recent Developments
  31. 8.6 AstraZeneca Plc
  32. 8.6.1 AstraZeneca Plc Company Information
  33. 8.6.2 AstraZeneca Plc Business Overview
  34. 8.6.3 AstraZeneca Plc Chagas Disease Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Plc Chagas Disease Drug Product Portfolio
  36. 8.6.5 AstraZeneca Plc Recent Developments
  37. 8.7 Oblita Therapeutics BVBA
  38. 8.7.1 Oblita Therapeutics BVBA Company Information
  39. 8.7.2 Oblita Therapeutics BVBA Business Overview
  40. 8.7.3 Oblita Therapeutics BVBA Chagas Disease Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Oblita Therapeutics BVBA Chagas Disease Drug Product Portfolio
  42. 8.7.5 Oblita Therapeutics BVBA Recent Developments
  43. 8.8 Merck & Co Inc
  44. 8.8.1 Merck & Co Inc Company Information
  45. 8.8.2 Merck & Co Inc Business Overview
  46. 8.8.3 Merck & Co Inc Chagas Disease Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Merck & Co Inc Chagas Disease Drug Product Portfolio
  48. 8.8.5 Merck & Co Inc Recent Developments
  49. 8.9 Kancera AB
  50. 8.9.1 Kancera AB Company Information
  51. 8.9.2 Kancera AB Business Overview
  52. 8.9.3 Kancera AB Chagas Disease Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Kancera AB Chagas Disease Drug Product Portfolio
  54. 8.9.5 Kancera AB Recent Developments
  55. 8.10 Humanigen Inc
  56. 8.10.1 Humanigen Inc Company Information
  57. 8.10.2 Humanigen Inc Business Overview
  58. 8.10.3 Humanigen Inc Chagas Disease Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Humanigen Inc Chagas Disease Drug Product Portfolio
  60. 8.10.5 Humanigen Inc Recent Developments
  61. 8.11 Grupo Praxis Pharmaceutical SA
  62. 8.11.1 Grupo Praxis Pharmaceutical SA Company Information
  63. 8.11.2 Grupo Praxis Pharmaceutical SA Business Overview
  64. 8.11.3 Grupo Praxis Pharmaceutical SA Chagas Disease Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Grupo Praxis Pharmaceutical SA Chagas Disease Drug Product Portfolio
  66. 8.11.5 Grupo Praxis Pharmaceutical SA Recent Developments
  67. 8.12 Daiichi Sankyo Co Ltd
  68. 8.12.1 Daiichi Sankyo Co Ltd Company Information
  69. 8.12.2 Daiichi Sankyo Co Ltd Business Overview
  70. 8.12.3 Daiichi Sankyo Co Ltd Chagas Disease Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Daiichi Sankyo Co Ltd Chagas Disease Drug Product Portfolio
  72. 8.12.5 Daiichi Sankyo Co Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Chagas Disease Drug Value Chain Analysis
  2. 9.1.1 Chagas Disease Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Chagas Disease Drug Sales Mode & Process
  6. 9.2 Chagas Disease Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Chagas Disease Drug Distributors
  9. 9.2.3 Chagas Disease Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst